Skip to content
Search our Site
Search our site
Search our site
My PD Journey
All research papers
About the EPDA
Political affairs and policy
All research papers
Search research papers
Resources and publications
ALL research papers
Verbascoside promotes the regeneration of tyrosine hydroxylase-immunoreactive neurons in the substantia nigra
After 6 weeks of verbascoside treatment, rat rotational behavior was alleviated; tyrosine hydroxylase mRNA and protein expression and the number of tyrosine hydroxylase-immunoreactive neurons in the rat right substantia nigra were significantly higher than the Parkinson's model group. These findings suggest that the mechanism by which verbascoside treats Parkinson's disease is related to the regeneration of tyrosine hydroxylase-immunoreactive neurons in the substantia nigra.
01 January 2016
Smoking in Patients with Parkinson's Disease: preliminary striatal DaT-SPECT findings
Conclusions: The lower [123I]FP-CIT uptake together with the lower UPDRS-III motor score observed in our current-smokers patients with Parkinson's disease (even taking into account variables that are probably expression of dopaminergic neuron decline and treatment) would support an effect of smoking on dopaminergic synaptic mechanisms.
14 December 2015
MicroRNA machinery in Parkinson's disease: a platform for neurodegenerative diseases
Authors evaluated the existing literature and arranged PD-associated miRNAs according to their mechanism of action, particularly apoptosis, autophagy, inflammation, mitochondrial dysfunction and oxidative stress. According to this arrangement, a majority of PD-associated miRNAs were indicated to influence autophagic/apoptotic pathways.
17 November 2015
Novel tactics for neuroprotection in Parkinson's disease: Role of antibiotics, polyphenols and neuropeptides
The present review summarizes three novel approaches, the use of which is promising in pre-clinical studies. Polyphenols have been shown to possess neuroprotective properties on account of their well-established antioxidative and anti-inflammatory actions but also due to their influence on protein misfolding and mitochondrial homeostasis.
02 November 2015
Sequence of electrode implantation and outcome of deep brain stimulation for Parkinson's disease
Conclusions: Authors observed a higher dispersion for the electrode on the second implanted side, which also resulted to be a significant predictor of motor outcome at 1 year.
09 September 2015
Impact of localisation of deep brain stimulation electrodes on motor and neurobehavioural outcomes in Parkinson's disease
Conclusions: Stimulation of zona incerta may influence appetite and weight gain. These clinical results seem to support a personalised DBS-targeted Parkinson therapy including individual motor and non-motor parameters.
21 August 2015
Dose-Response Analysis of the Effect of Carbidopa-Levodopa Extended Release Capsules (IPX066) in Levodopa-Naïve Parkinson's
Natural disease progression in early Parkinson's disease as measured by UPDRS was 11.6 units/year and faster in patients with more severe disease (Hoehn-Yahr stage 3). Maximum placebo/non-levodopa response was 23.0% of baseline UPDRS. Maximum levodopa effect from IPX066 was 76.7% of baseline UPDRS, and the ED50 was 450 mg levodopa.
18 January 2015
The Chemical Molecule B355252 is Neuroprotective in an In Vitro Model of Parkinson's Disease
Overall, this study demonstrates that death of neurons under toxic conditions characteristic of PD can be efficiently halted by B355252 and suggests that further development of the molecule could be potentially beneficial as a therapeutic prevention or treatment option for PD.
09 December 2014
Subscribe to this feed >
Back to Top
Add page to PDF basket
Copyright © 2016 EPDA. All Rights Reserved.
Privacy and cookies